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Abbreviations 
 
 
ACC, acetyl-CoA carboxylase; AMPK, AMP activated protein kinase; ALT, alanine 
aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; AS160, Akt 
substrate of 160 kDa; A1AT, ?1-antitrypsin; BMI, body mass index; CaMKK, calmodulin-
dependent protein kinase kinase; CAR; constitutive active/androstane receptor; c-DNA, 
complementary DNA; CK-18, cytokeratin-18; CREB, cyclic AMP response element binding 
protein; CT, threshold cycle; CTMP, carboxy-terminal modulator protein; DMEM, 
Dulbecco's modified Eagle's medium; ELISA, enzyme-linked immunosorbent assay; ER, 
endoplasmatic reticulum; FFA, free fatty acids; Foxo1 and 3, forkhead transcription factors; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GGT, ?-glutamyl transpeptidase; 
GLUT, glucose transporter; GSK-3?, glycogen synthase kinase 3?; GTT, glucose tolerance 
test; G6Pase, glucose-6-phophatase; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; 
HCV, hepatitis C virus; HFD, high fat diet; HNF4, hepatocyte nuclear factor 4; HOMA-IR, 
homeostasis model assessment of insulin resistance; Hsp90, heat shock protein 90; IDF, 
International Diabetes Federation; IFN?, Interferon ?; IL-6, interleukin-6; INR, international 
normalized ratio; IRS 1-4, insulin receptor substrates 1-4; ITT, insulin tolerance test; JNK, 
jun-N-terminal kinase; LXR, liver X receptor; MAPK, mitogen activated protein kinase; 
MEK, MAPK kinase; mRNA, messenger ribonucleic acid; mTOR, mammalian target of 
rapamycin; MTP, microsomal triglyceride transfer protein; NAFLD, non alcoholic fatty liver 
disease; NAS, NAFLD activity score; NASH, non alcoholic steatohepatitis; OA, okadaic acid; 
ORF, open reading frame; PDK1, phosphoinositide-dependent kinase 1; PEPCK, 
phosphoenolpyruvatcarboxykinase; PGC1?, peroxisome proliferator–activated receptor 1?; 
PHLPP?, PH domain leucine-rich repeat protein phosphatase ?; PIAS1, protein inhibitor of 
activated STAT 1; PIP3, phosphoinositol-3-phosphates; PI3K, phosphatidyl-inositol-3-
kinase; PKB/Akt, protein kinase B; PKC, protein kinase C; PP2Ac, protein phosphatase 2A 
catalytic subunit; PRMT1, protein arginine methyl transferase 1; qRT-PCR, quantitative (real 
time) reverse transcription polymerase chain reaction; PTEN, phosphatase and tensin 
homolog; SEM, standard error of the mean; SHIP, src-homology 2-containing inositol 5' 
phosphatase; SHP, small heterodimer partner; shRNA, short hairpin RNA; SH2, scr-
homology-2; SOCS, suppressor of cytokine signaling 3; SREBP1c, sterol regulatory element 
binding protein 1c; STAT, signal transducer and activator of transcription; SVR, sustained 
virologic response; TG, triglycerides; tg, transgenic; TMAO, trimethylamine N-oxide 
dihydrate; TNF?, tumor necrosis factor ?; TORC2, mTOR complex 2; TORC2, transducer of 
regulated CREB activity 2; TUDCA, tauroursodeoxycholic acid; T2DM, type 2 diabetes 
mellitus; UDCA, ursodeoxycholic acid; UPR, unfolded protein response; VLDL, very low 
density lipoprotein; 4-PBA, 4-phenyl butyric acid; 
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1. Introduction 
 
1. Hepatitis C Virus Infection 
Epidemiology and natural history of hepatitis C 
 
Hepatitis C Virus (HCV) infection is one of the major causes of chronic liver disease. 
According to recent WHO estimates, the prevalence of HCV is approximately 2.2% - 
affecting approximately 130 million people worldwide (1). There are different genotypes of 
the HCV virus. The most common genotypes are genotype 1, 2, 3 and 4. 
Severity of chronic hepatitis C is assessed by histological analysis of inflammation and 
fibrosis in a liver biopsy sample, according to a scoring system. The most widely used score 
is the Metavir score (2). Progression of chronic hepatitis C varies between individuals. Up to 
85% of patients infected with HCV develop chronic liver disease and are at risk for fibrosis 
progression to cirrhosis of the liver, which develops in 20-30% of cases (3). 
Cirrhosis in HCV infection is a common cause of hepatocellular carcinoma and end-stage 
liver disease, necessitating liver transplantation. Risk factors for a progressive course of 
chronic hepatitis C are age, male gender, alcohol consumption, diabetes and steatosis. 
Interestingly, when insulin resistance, an earlier and more sensitive parameter of glucose 
metabolism derangement, is added to logistic regression, the association between steatosis 
and fibrosis disappears (4). 
Until present there is no protective vaccine available. The current standard treatment is 
Peginterferon? combined with Ribavirin. It has to be given for 6 to 12 months dependent on 
the HCV genotype (5). Still, only 50% of patients reach a so-called “sustained virologic 
response (SVR)”, determined when there is no detectable HCV-RNA in the blood 6 months 
after the end of antiviral therapy, and can be considered as cured from HCV infection. 
Response to the treatment is monitored by HCV-RNA in the blood at weeks 4 and 12 of 
treatment and undetectable HCV-RNA is a good predictor of response (6). Response to 
therapy is dependent on HCV genotype and viral load. Further host factors such as age, race, 
body mass index (BMI), insulin resistance, hepatic steatosis and fibrosis might play a role (7, 
8). 
 
The Hepatitis C Virus 
 
The Hepatitis C Virus (HCV) has been discovered in 1989 (9). It is the sole member of the 
genus hepacivirus within the Flaviviridae family, an enveloped single stranded sense RNA 
virus. The positive stranded RNA genome comprises 9600 nucleotides. It contains a 5’ non 
coding region, a single long open reading frame (ORF) encoding a polyprotein precursor of 
approximately 3000 amino acids and a 3’ non coding region. The polyprotein precursor is 
posttranslationally processed by cellular and viral proteases into structural and non-structural 
proteins. The structural proteins include the core protein that forms the viral nucleocapsid and 
the envelope proteins E1 and E2. The nonstructural proteins include the NS2-NS3 
autoprotease, the NS3 serine protease (a RNA helicase), the NS4A cofactor for NS3, the 
NS4B involved in formation of intracellular membrane particles and the NS5A and NS5B 
RNA-dependent RNA polymerase (10, 11). 
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Insulin Resistance in chronic hepatitis C 
 
Over the past 10 years many epidemiological studies have pointed out the role of insulin 
resistance as an important host factor in chronic hepatitis C. Insulin resistance is defined as a 
condition where higher insulin concentrations are needed to achieve normal glucose 
metabolism or normal insulin concentrations fail to achieve normal glucose metabolism (12). 
It is the major pathogenic factor of type 2 diabetes mellitus (T2DM) and the metabolic 
syndrome. A well-accepted method to measure systemic insulin resistance in patients is by 
the HOMA-IR (Homeostasis model assessment of insulin resistance). It is calculated by the 
following formula: fasting glucose (mmol/l) x fasting insulin (mIU/l) /22.5 (13). Hepatic 
insulin resistance has to be distinguished from systemic insulin resistance as it affects only 
the liver and cannot be measured by the HOMA-IR. 
In chronic hepatitis C, prevalence of insulin resistance and the risk to develop T2DM are 
clearly increased compared to healthy subjects or subjects with chronic liver disease other 
than HCV, e.g. Hepatitis B Virus (HBV) infection (7, 14-19). 
A relationship between insulin resistance and the severity of chronic hepatitis C has been 
described. Several studies have identified insulin resistance and diabetes as independent 
predictors of fibrosis progression and development of cirrhosis (4, 20-24). Also resistance to 
antiviral therapy has been assigned to insulin resistance in clinical trials (21, 25, 26) and 
improvement of insulin resistance during therapy (27, 28) in SVR in response to antiviral 
treatment has been observed (25). 
Hepatic steatosis is the histopathological term for accumulation of triglycerides in 
hepatocytes and has also been associated to HCV infection (19). Experimental and clinical 
data have shown that HCV genotype 3a can directly induce lipid accumulation in hepatocytes 
by interference with VLDL (very low density lipoprotein) assembly and upregulation of 
sterol regulatory element binding protein 1c (SREBP1c) (29-33). In genotypes other than 3a, 
steatosis is a consequence of insulin resistance development and is therefore also related to 
fibrosis progression and resistance to antiviral therapy (7, 34). Metabolic aspects of chronic 
HCV infection therefore are to some extend similar to non alcoholic fatty liver disease 
(NAFLD). 
The relationship between insulin resistance and HCC remains to be further elucidated. A 
study of NAFLD propose a role for insulin resistance in carcinogenesis (35). 
Hence, insulin resistance and steatosis of the liver in a setting of chronic hepatitis C have 
clinical and prognostic implications (Figure 1). But pathogenesis of insulin resistance in HCV 
is still incompletely understood (see 1.6.) and its understanding would help to improve 
treatment and prevent complications. 
 
 
 
 
 
 
 
 
 
 
Figure 1: Insulin Resistance in chronic hepatitis C 
 
 
 8 
2. Non alcoholic fatty liver disease (NAFLD) 
 
Non alcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis that is 
not associated with significant consumption of alcohol or other liver disease. It is considered 
to be the liver manifestation of the metabolic syndrome, a prosperity disease with increasing 
prevalence. Presumably NAFLD is the most common chronic liver disease in the western 
world. The precise prevalence of NAFLD is unknown. Data from different studies varies 
according to the method used to detect steatosis and the population studied. A recent 
representative study estimated the prevalence of NAFLD and NASH in the general 
population at up to 33% and 17%, respectively, and 80% and 40%, respectively, in patients 
with metabolic syndrome (36-38). 
Simple fatty liver might be a benign disease. However in its progressive form “non alcoholic 
steatohepatitis” (NASH) up to 20% of patients will develop cirrhosis, and some of them will 
progress to liver failure (9%) or hepatocellular carcinoma (HCC) (1%) (39).  
Unfortunately there are currently no pharmacological therapy options for the prevention of 
NAFLD or progression of the disease. Standard of care are lifestyle modifications with 
weight loss by increase in physical activity and change in dietary habits. Insulin sensitizing 
and hepatoprotective drugs have been tested. So far no agent has been demonstrated to 
prevent disease progression (40, 41). 
Another difficulty in disease management is the inability to predict which patient will 
develop liver-related morbidity. Non-invasive markers predicting NASH in NAFLD patients 
are needed to identify patients at risk. In vivo assessment of cytokeratin-18 fragments in the 
blood has recently been proposed as a potential non-invasive marker for NASH (42, 43). 
Cytokeratin-18 is the major intermediate filament in the liver and is cleaved by caspases 
when hepatocytes undergo apoptosis (44). 
 
 
3. Overexpression of PP2Ac in chronic hepatitis C 
 
Interferon? (IFN?) signaling is inhibited in chronic hepatitis C 
 
Interferon? (IFN?) signaling is an important pathway activated in spontaneous response to 
HCV infection and in standard antiviral therapy. Resistance to IFN? signaling resulting in 
chronic HCV infection and non-response to treatment is still incompletely understood. 
Studies from our laboratory revealed that the expression of viral proteins in cells in culture 
and in B6HCV transgenic mice inhibits Jak-STAT signaling (45, 46). 
 
Protein Phosphatase 2A (PP2A) 
 
Phosphorylation and dephosphorylation of proteins are essential post-translational 
modifications in the regulation of signal transduction. Protein phosphatases therefore play an 
important role in regulating protein kinase cascades and the cellular localization of various 
proteins, e.g. transcription factors. There are several serine/threonine phosphatases described: 
PP1, PP2A, PP2B (calcineurin), PP2C, PP3, PP4 and PP5. 
PP2A is ubiquitously expressed in eukaryotic cells and represents approximately 1% of total 
cellular proteins (47). Deletion of PP2A catalytic subunit in mice is lethal supporting its 
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essential role (48). PP2A is a multimeric protein consisting of 3 subunits: a catalytic 36 kDa 
C subunit and a scaffolding 65 kDa A subunit (or PR65), which form a constitutive complex. 
Two isoforms of the C subunit and of the A subunit exist (? and ?). This A-C core dimer can 
interact with any of the various regulatory B subunits from three different families: B, B’ and 
B’’ (or PR55, PR61 and PR72). Assembly of distinct holoenzymes plays a role in directing 
the phosphatase to distinct substrates and to distinct cellular compartments (49). 
More than 30 protein kinase activities are influenced by PP2A in vitro and several kinases 
form complexes with PP2A (49). These kinases are involved in diverse cellular processes: 
metabolism, DNA replication, transcription, translation, cell-cycle progression, 
morphogenesis, development, transformation and stress response (50). Among the PP2A 
substrates there are PKB/Akt, PKC, p70S6Kinase, AMP Kinase, MEK, ERK, JNK (49, 51). 
The regulation of PP2A is tightly controlled (52). However, downregulation of PP2A by all-
trans-retinoic acid (53) or through peroxisome proliferator activated receptor ? (54) and 
upregulation through colony stimulating factor 1 have been reported (55). 
Okadaic acid (OA) is a natural inhibitor of PP2A. In vitro it inhibits PP2A with an IC50 of 
0.1nM. Below concentrations of 1 μM, OA has been considered to be selective for PP2A 
(56). 
 
Upregulation of PP2A inhibits IFN? signaling and increases viral replication 
 
Upregulation of Protein Phosphatase 2A (PP2A) was observed in HCV protein expressing 
cells, in the liver of B6HCV transgenic (tg) mice and in human liver biopsies from patients 
infected with HCV when compared to healthy controls (57). It has been shown that 
overexpression of PP2A inhibited protein arginine methyl transferase 1 (PRMT1) enzymatic 
activity and therefore lead to hypomethylation of STAT1. Hypomethylation of STAT1 
facilitates binding to its inhibitor protein inhibitor of activated STAT1 (PIAS1) that leads to 
decreased STAT1 binding to target genes in response to IFN? (57). Inhibition of PRMT1 by 
PP2A additionally leads to hypomethylation of viral helicase NS3 that increases NS3 
unwinding activity and therefore increases viral replication (58). Treatment with S-Adenosyl-
L-methionine and Betaine has been shown to restore STAT1 methylation, improve IFN? 
signaling, and antiviral response in hepatocytes in culture (59). In a clinical trial in the 
Department of Gastroenterology and Hepatology at the University Hospital in Basel we are 
currently testing whether addition of S-Adenosyl-L-methionine and Betaine to standard 
antiviral therapy can overcome resistance to antiviral therapy in HCV patients that did not 
respond to IFN? therapy, so called non-responders. 
Interestingly, PP2A is also overexpressed in HBV infection, a virus of the hepadnaviridae 
family of hepatotropic DNA viruses. In HBV expressing hepatoma cells and in liver biopsies 
of HBV infected patients we found an overexpression of PP2A and an inhibition of IFN? 
signaling (60). 
 
Viral induced ER stress response leads to the upregulation of PP2A  
 
The Endoplasmatic reticulum is a membranous network responsible for protein synthesis, 
protein folding and export to the Golgi complex. Folding is processed by foldases and 
facilitated by molecular chaperones that shield unfolded regions from surrounding proteins. 
Only correctly folded proteins are exported. During pathological stress situations such as 
viral infection but also glucose deprivation or lipid accumulation, the protein folding 
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machinery is overload with unfolded proteins and induces an unfolded protein response 
(UPR) or ER stress response (61, 62). The ER stress response induces an increase in folding 
capacity of the ER through transcriptional upregulation of genes, e.g. chaperones (63). Also 
chemical chaperones such as 4-phenyl butyric acid (4-PBA), trimethylamine N-oxide 
dihydrate (TMAO) and dimethyl sulfoxide can increase folding capacity of the ER (64). 
Recently it has been shown, that the ER stress response can induce insulin resistance in mice 
(65, 66). 
The fact that a RNA- and a DNA-virus both upregulate PP2A lead us to the study of virus 
induced endoplasmatic reticulum stress (ER stress). It is well known that viral infection can 
induce ER stress and indeed, it has been published that the expression of HCV structural 
proteins E1, E2 and HCV core induce an ER stress response (67-69). 
It has been shown in our laboratory that HBV and HCV are both able to induce an ER stress 
response. During ER stress a calcium release from the ER to the cytoplasm activates cyclic 
AMP response element binding protein (CREB). Activated CREB then binds to its binding 
site on the PP2A promoter region and upregulates its transcription (70). 
 
 
4. Regulation of glucose homeostasis in the liver 
 
The liver is the central organ in energy metabolism, and insulin is the primary anabolic 
hormone promoting energy storage in the fed state (71). High portal insulin concentrations 
rapidly trigger stimulation of glycogensynthesis, lipogenesis, inhibition of VLDL secretion 
and suppression of gluconeogenesis and glycogenolysis. These processes are regulated by 
phosphorylation and dephosphorylation of metabolic pathways, regulation of gene expression 
and mRNA stability (72, 73). Storage of glucose as glycogen and suppression of 
gluconeogenesis are regulated by insulin, glucose and the parasympathetic nerve (73). After 
an over night fast, up to 60% of circulating glucose are derived from hepatic glycogenolysis 
and at least 40% from gluconeogenesis. After prolonged fasting (24 to 36 hours) hepatic 
gluconeogenesis primarily from alanine is the sole source of blood glucose (74, 75).  
In peripheral tissues as muscle and adipose tissue, in the fed state insulin increases glucose 
uptake by translocation of the GLUT4 transporter to the cell surface (76). Up to 75% of 
insulin dependent glucose disposal occurs in skeletal muscle. 
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Insulin signaling 
 
The insulin receptor is ubiquitously expressed and is a member of the receptor tyrosine 
kinases. Insulin binding to the insulin receptor ?-subunit leads to a conformational change in 
the intracellular ?-subunit and to derepression of its tyrosine kinase domain resulting in 
transphosphorylation of the ?-subunit. When phosphorylated, tyrosine kinase domains have 
enhanced activity towards non-receptor substrates (77). There are different non-receptor 
substrates: insulin receptor substrates 1-4 (IRS-1, IRS-2, IRS-3, IRS-4), which are the most 
specific substrates, but also Gab-1, p60dok, Cbl, SHc and APS (78). Among these, IRS-1 and 
IRS-2 are best described and are expressed in many tissues, predominantly in the liver. IRS-1 
and IRS-2 knockout mice have an insulin resistant phenotype (79). 
The phosphorylated tyrosines in these substrates act as “docking sites” for scr-homology-2 
(SH2) domain containing proteins. Many of these proteins are adaptor proteins, the most 
important SH2 adaptor proteins are p85 and Grb-2 (79). Interaction of IRS to p85-PI3K leads 
to activation of PI3K p110 catalytic subunit, a central kinase in mediation of metabolic 
actions of insulin. PI3K activity can be inhibited by Wortmannin. It catalyses the 
phosphorylation of phosphoinositides on the 3-position generating phosphoinositol-3-
phosphates (PIP3) (80). Important inhibitors of this process are PTEN and SHIP. 
PIP3 regulate the AGC family of serine/threonine kinases, among them phosphoinositide-
dependent kinase 1 (PDK1) (81). Generation of PIP3 also leads to translocation of Protein 
kinase B (PKB/Akt) to the plasma membrane (82). PDK1 phosphorylates PKB/Akt on 
Thr308 in the kinase domain (81). Full activation of PKB/Akt further requires 
phosphorylation on Ser473 on its hydrophobic motif by mTOR complex 2 (TORC2) (83) 
leading to stabilization of the active conformational state (82, 84). PKB/Akt is a 
serine/threonine kinase that has a central role in transmission of insulin signal by 
phosphorylation of glycogen synthase kinase 3 (GSK-3), Forkhead transcription factors 
(FoxO1 and 3) and cAMP response element-binding protein (CREB) (79, 85). PKB/Akt can 
be negatively regulated by protein phosphatase 2A (PP2A) and PH domain leucine-rich 
repeat protein phosphatase (PHLPP?) by directly dephosphorylating S473 and/or Thr308 
(86, 87). Carboxy terminal modulator protein (CTMP) is another negative regulator that 
reduces PKB/Akt activity by binding to its carboxy-terminal domain and preventing its 
phosphorylation (88). 
Another downstream target of Akt is mTOR, an important kinase regulating protein 
synthesis, cell growth and metabolism (89). mTOR activation leads to a negative feedback 
loop to insulin signaling inducing phosphorylation of IRS-1 on Ser307 by S6Kinase, 
inhibiting its tyrosine phosphorylation (90).  
PKB/Akt phosphorylates and inactivates GSK-3 hereby inducing activation of glycogen 
synthase in order to increase glycogen synthesis (91). One the other hand, by phosphorylation 
induced nuclear exclusion of Foxo1, PKB/Akt inhibits expression of key enzymes of 
gluconeogenesis: phosphoenolpyruvatcarboxykinase (PEPCK) and glucose-6-phophatase 
(G6Pase) (92, 93). Akt induced inhibition of gluconeogenesis involves Foxo1 interaction 
with peroxisome proliferator–activated receptor 1? (PGC1?) (94-96). It has been reported 
recently, that PKB/Akt might directly inhibit PGC1? by phosphorylation and prevention of 
promoter binding (97). 
In the liver insulin signaling thereby is a crucial pathway for the regulation of 
glycogensynthesis and glycogenolysis, gluconeogenesis but also lipogenesis (79). 
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Figure 2: Regulation of glucose metabolism in the liver (79) 
In hepatocytes insulin stimulates the utilization and storage of glucose as glycogen and lipid  
by stimulating glycogensynthase and citrate lyase and upregulation of SREBP, ACC and 
FAS. It further inhibits the production of glucose from aminoacids by inhibition of Forkhead 
transcription factors, PGC1? and HNF4. 
 
AMP activated kinase (AMPK) 
 
AMP activated kinase (AMPK) is an energy sensor that regulates cellular metabolism in 
response to nutrient deficiency. When AMP levels are high, AMPK is activated leading to 
stimulation of energy producing processes such as glucose uptake or lipid oxidation and to 
inhibition of energy consuming pathways such as gluconeogenesis or lipogenesis. It controls 
whole body energy homeostasis by the regulation of glucose- and lipid-metabolism in 
multiple tissues (98). 
AMPK is a heterotrimeric protein consisting of a catalytic ? and regulatory ? and ? subunits. 
Upon AMP binding to the ? subunit, AMPK is allosterically activated and phosphorylated on 
Thr172 by the upstream kinase LKB1 (99) or through rise in intracellular Ca2+ ions by 
CaMKK (100). In the liver, activation of AMPK leads to suppression of gluconeogenesis 
regulated by PEPCK and G6Pase. Gluconeogenesis is insufficiently suppressed in liver 
specific AMPK?2 knockout mice (101). 
Metformin is a drug widely used as a treatment for type 2 diabetes mellitus since 1979. It 
inhibits hepatic gluconeogenesis and therefore improves blood glucose levels. Recently, it 
has been shown that metformin induces phosphorylation on Thr172 and activation of AMPK. 
In this model, AMPK phosphorylates TORC2 leading to its nuclear exclusion and thereby 
prevents transcriptional induction of gluconeogenic key enzymes by PGC1? coactivation 
(102). A second model for metformin induced suppression of gluconeogenesis hints at 
involvement of AMPK induced upregulation of small heterodimer partner (SHP) (103). 
There is evidence that PP2A regulates AMPK. Indeed, inhibition of PP2A by Okadaic acid 
lead to AMPK phosphorylation in rat hepatocytes (104). PP2A was described to inactivate 
AMPK in pancreatic ?-cells (105) and inhibit AMPK phosphorylation in vascular endothelial 
cells (106). 
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Liver X receptor (LXR) 
 
Nuclear receptors are ligand activated transcription factors that regulate gene expression in 
response to hormonal and environmental factors. Liver X receptors (LXR? and LXR?, also 
known as NR1H3 and NR1H2) are nuclear receptors that play an important role in the 
transcriptional regulation of cholesterol- and fatty acid- but also glucose metabolism. 
Furthermore they have been implicated in the control of immune response and inflammation 
and might therefore integrate metabolic and inflammatory signaling pathways (107). 
Oxidized metabolites of cholesterol – so called oxysterols – are the natural ligands of LXR 
(108). There are two LXR isoforms: LXR? is highly expressed in the liver and at lower levels 
in intestinal, adrenal glands, adipose tissue, macrophages and kidney whereas LXR? is 
ubiquitously expressed (109). 
Recently it has been published that glucose and glucose-6-phosphate can directly bind to and 
activate LXR (110). Though it is not completely understood how glucose, a hydrophilic 
ligand, can bind to the hydrophobic ligand binding pocket of LXR (111), this finding shows 
that not only insulin but also glucose itself has an effect on hepatic glucose homeostasis 
regulation. 
Upon ligand binding, LXR forms heterodimers with the retinoid X receptor (RXR), recruites 
coactivators or corepressors in order to regulate target gene expression (112). It has been 
shown, that treatment with LXR agonists improves glucose tolerance in diabetic mice and 
rats (113, 114). This effect was at least partially due to decreased hepatic gluconeogenesis by 
inhibition of the gluconeogenic key enzymes PEPCK and G6Pase. Interestingly glucose, 
similar to oxysterol LXR ligands, inhibits expression of PGC1?, PEPCK and G6Pase in 
HepG2 cells grown in low glucose media (110). 
LXR as well as other nuclear receptors have recently been found to be phosphorylated 
proteins (115). It was shown that LXR? is phosphorylated on Serine 198. There is growing 
evidence that phosphorylation of LXR might regulate LXR induced gene expression (116, 
117). The role of PP2A as a serine/threonine kinase in regulating LXR has to be elucidated. 
Another hepatic nuclear receptor involved in regulation of gluconeogenesis is constitutive 
active/androstane receptor (CAR) (118). It has been described that activation of CAR by 
phenobarbital leads to a complex formation of the CAR-Hsp90 complex with PP2A (119). Its 
translocation to the nucleus as the initial step for activation by phenobarbital is regulated by 
dephosphorylation at Ser202a (120). Whether CAR is dephosphorylated on serine 202 by 
PP2A is discussed but needs to be proven. 
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5. Insulin resistance in the pathophysiology of chronic liver disease 
 
Insulin resistance development by hepatitis C virus 
 
Unless insulin resistance development in chronic hepatitis C is well documented, it is not yet 
completely understood how the HCV virus interferes with metabolic signaling pathways. 
Different models of HCV induced induction of steatosis and insulin resistance come from 
HCV transgenic mouse models. 
One of the HCV core transgenic (tg) mice, that expresses the core of HCV genotype 1b under 
the control of HBV regulatory elements (31) developed an insulin  resistant state at the age of 
2 months and steatosis of the liver at the age of ? 3 months (121). When fed with a high fat 
diet, HCV core tg mice developed diabetes due to TNF? induced impaired IRS1-Y 
phosphorylation (121). A mechanism dependent on the proteasome activator PA28? for HCV 
core induced insulin resistance development through degradation of IRS2 and 
hypophosphorylation of IRS-1 and PKB/Akt has been proposed (122). Moreover it has been 
shown that HCV core protein interferes with the activity of the hepatic microsomal 
triglyceride transfer protein (MTP) thereby inhibiting very low density lipoprotein (VLDL) 
assembly and inducing hepatic steatosis (32). 
Similarly, HCV tg mice that express either the entire HCV polyprotein or the HCV structural 
proteins of genotype 1b under the control of an albumin promoter develop hepatic steatosis at 
the age of ? 10 months (123). 
Finally, a third model of HCV tg mice, the B6HCV mice, express the entire HCV ORF 
genome of genotype 1b under the control of a hepatocyte specific ?1-antitrypsin promoter 
(A1AT) (46, 124). Steatosis and inflammatory infiltrates were detected at an age of 3 to 18 
months (46, 124). As mentioned, we observed overexpression of PP2A in the liver of these 
mice (57). 
It has been observed that IRS-1 and -2 protein levels were downregulated in HCV patient 
liver biopsies with fibrosis progression, in the liver of HCV core tg mice and HCV core 
expressing HepG2 cells (125). A cell culture model has been developed where Suppressor of 
cytokine signaling 3 (SOCS3) upregulation leading to degradation of IRS-1 and -2 would 
inhibit insulin signaling at the levels of of PI3K and PKB/Akt phophorylation (125). In HCV 
patients with sustained virologic response (SVR) after antiviral treatment, IRS-1 and -2 
expression increased consistent with lower HOMA (126). 
Decreased IRS-1 expression has also been observed in HCV core expressing Huh7 cells of 
both HCV genotype 3a and 1b (127). Unless different clinical studies have found an 
upregulation of SOCS3 in patients with HCV and insulin resistance (128, 129), SOCS3 
expression was normal in these cell culture systems. HCV core induced IRS-1 degradation 
has been found to be genotype specific, involving SOCS7 in genotype 3a but mTOR in 
genotype 1b (127). 
Further insulin signaling has been studied in 42 biopsies from non-obese and non-diabetic 
HCV patients and 10 non-healthy controls. In this study, insulin receptor and IRS-1 
expression was intact but tyrosine phosphorylation of IRS-1 and its association with PI3K, 
and PKB/Akt phosphorylation were inhibited (130). 
It is further interesting that PP2A, that is upregulated by a HCV induced ER stress response, 
interferes with insulin signaling in adipocytes. Indeed in 3T3-L1 cells, PP2A negatively 
regulates the insulin signaling cascade at the level of PKB/Akt and GSK3? phosphorylation 
whereas IRS-1 expression and IRS-1 tyrosine phosphorylation were not affected (131). 
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Insulin resistance as a key factor in pathogenesis of NAFLD 
 
Little is known about the pathophysiology and natural history of NAFLD and NASH. A so 
called “two hit hypothesis” has been proposed in 1998 (132). In this model insulin resistance 
plays a key role in the initiation of the disease or “first hit”. The second hit is still 
controversially discussed (36). Oxidative stress and cytokine mediated liver-injury might play 
a role (133). 
Hypothetical models support subsequent development of peripheral and later hepatic insulin 
resistance. Peripheral insulin resistance increases flux of free fatty acids (FFA) to the liver by 
increased ?-oxidation in the adipose tissue whereas hepatic insulin resistance promotes 
increased de novo lipogenesis both leading to hepatic triglyceride accumulation (134). 
In addition to these two mechanisms, lipid accumulation in hepatocytes can theoretically 
result from impairment in oxidation of FFA at the mitochondria or export of TG in form of 
VLDL particles (135). 
Indeed, obesity might lead to peripheral insulin resistance and secretion of proinflammatory 
cytokines from the adipose tissue inducing peripheral and also hepatic insulin resistance. It 
has been shown that chronic exposure to IL-6 leads to hepatic insulin resistance in mice 
(136). Also chronic exposure to TNF? has been shown to inhibit insulin signaling in HepG2 
(137, 138). 
Interestingly there is a role for ER stress in insulin resistance development. Leptin deficient 
ob/ob mice and mice on high fat diet revealed obesity induced ER stress response, leading to 
hyperactivation of Jun N-terminal Kinase (JNK) and inhibition of insulin signaling by serine 
phoshorylation of IRS-1 (65). It was shown that 4-phenyl butyric acid, a chemical chaperone, 
alleviates ER stress and restores hepatic insulin signaling and systemic insulin sensitivity in 
ob/ob mice (66). 
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2. Aims 
 
1. Insulin Resistance in the pathophysiology of chronic hepatitisC 
 
The aim of the project was to study the pathophysiology of insulin resistance in chronic 
hepatitis C.  
 
We hereby studied the role of hepatic Protein Phosphatase 2 A (PP2A) overexpression and its 
interference with 
 Insulin signaling, 
 AMPK signaling and 
 Glucose induced regulation of gluconeogenesis. 
  
Based on the concept that insulin resistance is involved in disease progression and therapy 
resistance, a better understanding of these mechanisms is required for future development of 
more effective antiviral drugs to cure HCV infection or slow down fibrosis progression. 
 
2. Insulin Resistance in the pathophysiology of NAFLD 
 
The aim of the second project was to characterize a cohort of patients with non alcoholic fatty 
liver disease (NAFLD). 
 
We investigated the discrepancy between NAFLD patients and patients with advanced stage 
of NAFLD: non alcoholic steatohepatitis (NASH) concerning 
 Clinical and laboratory tests and 
 Cytokeratin-18 fragmentation in the serum. 
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3. Material and Methods 
 
Material and methods of the experiments shown in result section 4.1. “Virus induced over-
expression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C” are 
described there. Additional material and methods are described below. 
 
Reagents, Antibodies and Cells 
LXR? antibody was from R&D Systems Europe (Oxon, United Kingdom), LXR? antibody 
from Abcam (Cambridge, United Kingdom). 
Moloney murine leukemia virus reverse transcriptase, random hexamers and 
deoxynucleoside triphosphate were from Promega Biosciences Inc. (Wallisellen, 
Switzerland). qRT-PCR primers were synthesized by Microsynth, SYBR-Green PCR Master 
Mix was obtained from Applied Biosystems (Foster City, CA). 
HA-PP2A cells are Huh7 derived cells stably expressing a HA-tagged PP2A catalytic subunit 
(PP2Ac). They are grown in DMEM, 10% fetal bovine serum, supplemented with penicillin/ 
streptomycin and 800 μg/ml of G418. Glucose free DMEM was obtained from Invitrogen 
(Lubioscience, Lucerne, Switzerland). 
 
Quantitative RT-PCR 
Total RNA extraction from human liver biopsy samples was done using NucleoSpin RNA II 
Kit (Macherey-Nagel, Oensingen, Switzerland) for mouse liver and cultured cells or 
RNAeasy mini Kit (Quiagen, Basel, Switzerland) for human liver biopsies according to 
manufacturer’s instructions. RNA was reverse transcribed by reverse transcriptase in the 
presence of random hexamers and deoxynucleoside triphosphate. The reaction mixture was 
incubated for 5 minutes at 70°C and then for 1 hour at 37°C and was stopped by heating at 
95°C for 5 minutes.  
The cDNA was used to perform SYBR-PCR based on SYBR-Green-Fluorescence. To 
prevent influence from genomic DNA amplification, the primers were designed across exon-
intron junctions. All reactions were run in duplicate using the ABI 7000 Sequence Detection 
System (Applied Biosystems). Relative mRNA expression levels were calculated from ?ct 
values. The ?ct value was derived by subtracting the threshold cycle (CT) value for GAPDH, 
which served as an internal control, from the CT values for the different genes. 
 
Human primers: 
GAPDH_forward 5’-GCTCCTCCTGTTCGACAGTCA-3’  
GAPDH_reverse 5’-ACCTTCCCCATGGTGTCTGA-3’ 
LXR?_forward 5’- CCCTTCAGAACCCACAGAGATC -3’ 
LXR?_reverse  5’- CCCACACACGCTGCATAGC -3’ 
LXR?_forward 5’- AAGAGGAGGACGAAGAAAAGCA -3’ 
LXR?_reverse  5’- CCTCTCGCGGAGTGAACTACTC -3’ 
CAR_forward  5’- CACATGGGCACCATGTTTGA -3’ 
CAR_reverse  5’- AAGGGCTGGTGATGGATGAA -3’ 
PGC1?_forward 5’- CAAATGCACCTCCAAAAAGAAGTC -3’ 
PGC1?_reverse 5’- TTGTTGGTTTGGCTTGTAAGTGTT -3’ 
PEPCK_forward 5’- CGCCATGCGCTCTGAGT -3’ 
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PEPCK_reverse 5’- GGGTCGTGCATGATGATCTTC -3’ 
G6PAse_forward 5’- GCTGCTCATTTTCCTCATCAAGT -3’ 
G6Pase_reverse 5’- AAAGTTTCTGCAACAGCAATGC -3’ 
GLUT2_forward 5’- TATCAGGACTATATTGTGGGCTAATTTC -3’ 
GLUT2_reverse 5’- AGAGCGGTTGGAGCAATTTC -3’ 
 
Mouse primers: 
GAPDH_forward  5’- AAAGTGGACATTGTTGCCATCAAC -3’ 
GAPDH_reverse 5’- GTTCACACCCATCACAAACATGGG -3’ 
LXR?_forward 5’- GAGTGTCGACTTCGCAAATGC -3’ 
LXR?_reverse  5’- TCAAGCGGATCTGTTCTTCTGA -3’ 
LXR?_forward 5’- CCCCACAAGTTCTCTGGACACT -3’ 
LXR?_reverse  5’- TGACGTGGCGGAGGTACTG -3’ 
CAR_forward  5’- CATTGCGGCGAGCCA -3’ 
CAR_reverse  5’- GCTGATTCAGTTGCAAAGATGC -3’ 
PGC1?_forward 5’- AGCCGTGACCACTGACAACGAG -3’ 
PGC1?_reverse 5’- GCTGCATGGTTCTGAGTGCTAAG -3’ 
PEPCK_forward 5’- CATAACGGTCTGGACTTCTCTGC -3’ 
PEPCK_reverse 5’- GAATGGGATGACATACATGGTGCG -3’ 
G6PAse_forward 5’- ATGAACATTCTCCATGACTTTGGG -3’ 
G6Pase_reverse 5’- GACAGGGAACTGCTTTATTATAGG -3’ 
 
Fasting glucose, insulin and HOMA in mice 
Mice were fasted o/n. Glucose was measured in mice fasted o/n from tail vein blood by 
Ascensia Contour blood glucose monitoring system (Bayer AG Health Care, Zurich, 
Switzerland). Insulin was measured from 5μl serum using Mercodia Ultrasensitive Mouse 
Insulin ELISA (Mercodia, Uppsala, Sweden). HOMA-IR was calculated by the formula: 
fasting glucose (mmol/l) x fasting insulin (mIU/l) /22.5 (13). 
 
Glucose and insulin tolerance tests in mice 
For the glucose tolerance test, mice were fasted o/n and glucose solution in saline was 
injected i.p. at 2g/kg body weight. Glucose was measured from tail vein blood before and 15, 
30, 45, 60, 90 and 180 minutes after injection using Ascensia Contour blood glucose 
monitoring system. 
For insulin tolerance test, mice were fasted for 4 hours and insulin solution was injected at 
0.8 IU/kg body weight. Glucose was measured from tail vein blood before and 15, 30, 45, 60 
and 90 minutes after injection. 
 
The Basel NAFLD cohort study 
The NAFLD cohort study is a prospective, long-term single center cohort study and has been 
established at the Department for Gastroenterology and Hepatology of the University 
Hospital in Basel in March 2003. Since December 2007 a second center was built up at the 
University Hospital in Zurich. Only patients with the histological diagnosis of NAFLD are 
recruited. 
The aim of the study is to do a long-term observation of patients with NAFLD with or 
without NASH with the documentation of relevant anamnestic, physiologic, biochemical and 
histological parameters. This set of data might help to find out the number of patients that 
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progress from NAFLD to NASH or from NASH to NASH cirrhosis, respectively. Further to 
detect patients at risk for a progressive form of the disease. Finally to build up a serum-, 
plasma- and biopsy bank which enables us to investigate the use of emerging new tools. 
Patients are seen once per year. The visits include personal and family anamnesis for diseases 
of the metabolic syndrome, dietary habits, sports, drugs and alcohol intake. Patients are 
examined focusing on blood pressure, heart rate, weight, BMI, waist circumference. Further a 
fasting blood sample is taken for analysis of glucose, insulin, c-peptide, triglycerides, 
cholesterol, AST, ALT, GGT, AP, bilirubin, albumin, INR, hematology. An oral glucose 
tolerance test is performed in patients without diagnosis of diabetes mellitus. ?-fetoprotein is 
measured in patients with cirrhosis. By abdominal sonography, liver, pancreas and spleen are 
examined with a focus on steatosis of the liver, pancreatic lipomatosis and visceral fat 
accumulation. 
Cytokeratin-18 fragments were measured using the M30-Aptosense ELISA Kit, Alexis 
Biochemicals (Grünwald, Germany). 
 
Statistical analysis 
Box plot diagrams, Mann Whitney tests, t-tests and Spearman correlations were performed 
using GraphPad Prism version 4.00 for Macintosh, GraphPad Software, San Diego California 
USA. Multivariate regression analysis was done using STATA/SE software, StataCorpLP, 
Texas, USA. 
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4. Results 
 
1. Virus induced over-expression of protein phosphatase 2A inhibits 
insulin signaling in chronic hepatitis C 
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2. Overexpression of PP2A dysregulates glucose induced gene 
regulation – a role in Liver X receptor (LXR) regulation? 
 
LXR in PP2Ac expressing cells (Huh7 vs. HA-PP2A cells) 
 
Glucose metabolism in the liver is regulated not only by insulin but also by glucose itself. 
It has been shown recently, that glucose is a ligand at the LXR? and –? receptors and inhibits 
expression of gluconeogenic genes (110).  
First we analysed mRNA and protein expression of LXR? and LXR? in Huh7 and in Huh7 
cells stably transfected with a constitutive active PP2Ac (HA-PP2A cells) by quantitative 
RT-PCR and Western Blot. There was no significant difference in mRNA or protein 
expression of both nuclear receptors (Figure 3A). 
To test whether glucose induced inhibition of gluconeogenic genes is affected by PP2A, 
Huh7 and HA-PP2A cells were grown in glucose free medium and treated with glucose 
20mM overnight. Gene expression of PGC1?, PEPCK and G6Pase was analysed by 
quantitative RT-PCR. We observed that inhibition of PGC1? and PEPCK was attenuated in 
HA-PP2A cells. Unexpectedly G6Pase was not inhibited but upregulated by glucose 
treatment in both cell lines. This upregulation was again attenuated in HA-PP2A cells (Figure 
3B). These data suggest that PP2A negatively regulates glucose induced and presumably 
LXR dependent regulation of gluconeogenesis. 
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Figure 3: PP2A does not influence LXR expression but glucose induced gene regulation by 
LXR. 
A) PP2A does not influence mRNA- and Protein expression of LXR? and LXR? in Huh7 and 
HA-PP2A cells. LXR? and LXR? mRNA expression was assessed by quantitative RT-PCR 
from 3 independent experiments from Huh7 and HA-PP2A RNA-extracts. Relative mRNA is 
shown as the number of copies relative to GAPDH (left), statistical analysis was done using a 
two-tailed unpaired t-test. Protein levels were analysed by Western Blot from whole cell 
extracts from Huh7 and HA-PP2A cells, from U2OS cells as a negative control and from a 
homogenized sample of human liver biopsy as a positive control. Shown is a representative 
Western Blot for 2 independent experiments (right). 
B) Glucose induced regulation of gluconeogenic key enzymes is impaired in HA-PP2A cells. 
Huh7 and HA-PP2A cells were grown in glucose free medium and stimulated with glucose 
20mM overnight (o/n). Quantitative RT-PCR for indicated genes was done in duplicate in 3 
independent experiments. Relative mRNA expression is shown as a fold increase relative to 
the Huh7 untreated sample. Fold inhibition (for PGC1? and PEPCK) or fold increase (for 
G6Pase) of gene expression by glucose in Huh7 and HA-P2A cells is indicated as Fold (G). 
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LXR in vivo 
 
To investigate nuclear receptor expression in vivo, we further analysed mRNA expression of 
LXR?, LXR? and CAR in the liver of C57BL6 and B6HCV mice. Mice were starved for 8 
hours. We found LXR? and CAR significantly lower expressed in B6HCV mice whereas 
LXR? mRNA expression did not differ (Figure 4A). 
In liver biopsies from patients with chronic hepatitis C and control patients, we found no 
significant differences in the mRNA expression levels of LXR? and LXR?. However, CAR 
expression was significantly lower in HCV patient liver biopsies in consistence with the data 
in B6HCV mice (Figure 4B). Biopsies of patients are systematically taken after overnight 
fasting, and glucose levels are normal (< 7mmol/l) in non-diabetic patients. 
 
 
 
Figure 4: Expression of LXR?, LXR? and CAR in B6HCV mice and human liver biopsies. 
A) Expression of LXR? and CAR but not LXR? is decreased in B6HCV mice. C57BL6 and 
B6HCV mice were starved for 8 hours (n=6 of each group). RNA was extracted from liver 
homogenates and mRNA expression of LXR?, LXR? and CAR was assessed by quantitative 
RT-PCR. mRNA expression is shown as the number of copies relative to GAPDH. Statistical 
analysis was done using a two-tailed unpaired t-test (**, p=<0.01). 
B) Expression of CAR but not LXR is lower in human liver biopsies from HCV patients. RNA 
was extracted from human liver biopsy samples of control (n=10) and HCV (n= 28) patients. 
Expression of LXR?, LXR? and CAR mRNA was analysed by qRT-PCR and data was 
expressed as described in 4A. Statistical analysis was done using a two-tailed Mann Whitney 
test (**, p=<0.01). 
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3. Increase in gluconeogenesis as the key mechanism of HCV 
induced insulin resistance by PP2A ? 
 
PP2Ac overexpression increases gluconeogenic gene expression in cell culture 
 
From our experiments in cell culture we know that regulation of glucose homeostasis by 
insulin signaling, AMPK signaling and probably also LXR is inhibited when PP2A is 
overexpressed. These 3 pathways have one common endpoint: inhibition of gluconeogenesis. 
We therefore questioned whether inappropriate inhibition of gluconeogenesis is the key 
mechanism of HCV induced insulin resistance related to hepatic overexpression of PP2A. 
To answer this question we studied gene expression of PGC1?, the main transcriptional 
coactivator for gluconeogenic genes, and PEPCK and G6Pase mRNA expression in Huh7 
and HA-PP2Ac cells. We studied gene expression under low (5mM) and high (25mM) 
glucose conditions. 
At least under high glucose conditions, expression of PGC1?, PEPCK and G6Pase was 
upregulated in HA-PP2A cells, implicating increased glucose production in cells 
overexpressing PP2A (Figure 5A). 
On the other hand, when we inhibited PP2A activity in Huh7 cells by stimulation with low 
dose okadaic acid overnight, PGC1?, PEPCK and G6Pase were downregulated (Figure 5B). 
Interestingly, when we decreased PP2Ac expression by silencing with shRNA against 
PP2Ac?, PGC1? was downregulated but not PEPCK and G6Pase (Figure 5C). 
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Figure 5: PP2Ac expression upregulates PGC1?, PEPCK and G6Pase in cell culture. 
A) Huh7 and HA-PP2A cells were grown in low (5mM, left) and high glucose medium 
(25mM, right), respectively. Expression of PGC1?, PEPCK and G6Pase mRNA was 
analysed by qRT-PCR. Data from 3 independent experiments is shown as fold increase of 
gene expression in HA-PP2A cells compared to Huh7. 
B) Huh7 cells were grown in low (left) and high (right) glucose medium and treated +/- 
Okadaic Acid (OA) 25nM o/n. Expression of PGC1?, PEPCK and G6Pase was analysed by 
qRT-PCR. Data from 3 independent experiments is shown as fold increase of gene 
expression in OA treated cells compared to non-treated Huh7. 
C) Huh7 cells transfected with a shRNA vector against PP2Ac? and scrambled shRNA were 
grown in low (left) and high (right) glucose medium. Gene expression was analysed by qRT-
PCR and shown as fold increase in gene expression in PP2Ac? silenced cells compared to 
cells transfected with scrambled shRNA. 
 
 
B6HCV mice have an insulin resistant phenotype 
 
In B6HCV mice, development of steatosis has been described but until present it is not 
known whether they develop insulin resistance. We have shown that insulin signaling is 
inhibited and AMPK is hypophosphorylated in B6HCV mice (section 4.1). To find out 
whether inhibition of these metabolic signaling pathways has any physiologic consequence, 
we analysed glucose homeostasis in these mice. 
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Fasting insulin and glucose were measured and HOMA-IR was calculated. Interestingly both 
fasting glucose and insulin were significantly higher in B6HCV mice. Therefore HOMA 
index, a parameter of peripheral insulin resistance, is significantly higher in B6HCV mice 
(Figure 6A). 
A glucose tolerance test in B6HCV mice showed a higher increase in blood glucose 15 min. 
after glucose administration but decline was similar to C57BL6 mice. The insulin tolerance 
test shows, that insulin administration still induces glucose uptake into the muscle in B6HCV 
mice, but glucose levels remained higher at all time points in B6HCV mice (Figure 6B). 
Taken together B6HCV mice have an insulin resistant phenotype. 
 
 
 
Figure 6: B6HCV mice have an insulin resistant phenotype. 
A. Mice were starved o/n and fasting glucose and insulin levels were measured from tail vein 
blood (n=6 of each group). Glucose values are shown in mmol/l, insulin levels in mIU/l. 
HOMA-IR was calculated (fasting glucose x fasting insulin /22.5). Glucose (p=0.0098), 
insulin (p=0.047) and HOMA (p=0.0224) are significantly higher in B6HCV mice using a 
two-tailed unpaired t-test. Weight (in g body weight) did not differ significantly. 
B. Glucose (GTT) – and insulin tolerance tests (ITT) were done in 3 mice of each group. 
Glucose (dose: 2 mg/kg body weight) and insulin (dose: 0.8 IU/kg body weight) were 
administered i.p. and glucose was measured from tail vein blood at given time points. Data is 
shown as mean values +/- SEM. C57BL6 grey line, B6HCV black line. 
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Gluconeogenic gene expression in B6HCV mice 
 
To investigate further the reason for insulin resistance and high fasting glucose values in 
B6HCV mice, we measured mRNA expression of PGC1?, PEPCK and G6Pase by 
quantitative RT-PCR under fasting conditions. 
PGC1? was significantly upregulated in B6HCV mice. Surprisingly and contradictory to our 
results in vitro, there was no significant difference in expression levels of PEPCK and 
G6Pase (Figure 7). 
 
 
 
Figure 7: Transcriptional regulation of gluconeogenic enzymes in B6HCV and control mice. 
Mice were fasted for 8 hours (n=6 of each group). RNA was extracted from snap frozen liver 
tissue and transcribed to c-DNA. Relative mRNA expression was analysed using quantitative 
RT-PCR and shown as the number of copies relative to GAPDH. Statistical analysis was 
done using a two-tailed unpaired t-test (*, p<0.05). 
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Gluconeogenic gene expression in patients with chronic hepatitis C 
 
We further analysed expression of gluconeogenic genes in 28 liver biopsies from HCV 
infected patients and 10 biopsies from healthy controls. Naturally patients were starved 
overnight at the time point of liver biopsy and had normal blood glucose levels. 
In accordance with the findings in B6HCV mice, we found a significant upregulation of 
PGC1? but not PEPCK or G6Pase mRNA expression in HCV patients (Figure 8). 
Interestingly we also found that GLUT2, the major glucose transporter in the liver, is 
expressed at lower levels in the HCV group, suggesting lower hepatic glucose uptake. 
 
 
 
Figure 8: Transcriptional regulation of gluconeogenic enzymes in HCV patients 
A small part of the liver biopsy samples from 28 HCV and 10 control patients was stabilized 
in RNA later and frozen. RNA was extracted and transcribed to c-DNA. Relative mRNA 
expression was analysed using quantitative RT-PCR and shown as the number of copies 
relative to GAPDH. Statistical analysis was done using two-tailed Mann Whitney Test (*, 
p<0.05). 
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4. Insulin Resistance and natural history of NAFLD and NASH – first 
data from the NAFLD Cohort study in Basel 
 
Patient characteristics of the Basel NAFLD cohort study population 
 
Since March 2003 we have included 57 patients with histological diagnosis of NAFLD (22 
patients, 39%) or NASH (35 patients, 61%) into the cohort study. Follow up of patients is 
done once per year and during this time period, 40 patients have completed follow up visit 1, 
24 completed follow up visit 2, 17 completed follow up visit 3 and 8 completed follow up 
visit 4. 11 patients stopped study participation for different reasons. We included 37 male 
patients and 20 female patients whereas mean age at entry was 44 years for male and 50 years 
for female patients. 
Descriptive statistics given here are calculated from the data collected at baseline visits of the 
57 patients included. Longitudinal observations cannot be calculated yet as follow up of 
patients over a defined period has not been completed. 
Analysis of the liver histology shows that most of the patients have severe steatosis. Steatosis 
was staged according to the NAS scoring system (139). 18% of patients had only mild 
steatosis (5-33% of surface area of hepatic parenchyma), 28% had moderate steatosis (34-
66%) and 54% of patients had severe steatosis (? 67%). Within the NASH group, 7 patients 
(12% of all patients) present histological features of cirrhosis at the date of liver biopsy. 
NAFLD has been referred to as the liver manifestation of the metabolic syndrome. Metabolic 
syndrome according the criteria of the International Diabetes Federation (IDF) (140) was 
diagnosed in 51% of patients at baseline. Preliminary data shows that another 7.5% 
developed metabolic syndrome during the observation period. Most of the patients had 
overweight or adiposity while only 14% had normal BMI (BMI <25 kg/m2) and 12% had 
normal waist circumference (<94 cm for male and <80 cm for female patients). 
Diabetes was present in 18% of patients at baseline. Preliminary data shows that another 10% 
developed diabetes during follow up. On the other hand, insulin resistance measured by 
HOMA-IR, a major pathogenic factor of both metabolic syndrome and NAFLD, was seen in 
78% of patients. Also dyslipidemia, defined as hypertriglyceridemia or hypercholesterolemia, 
was frequently observed in our study population (72%). Hypertension was seen in 35% of 
patients and only 4% had coronary heart disease. 
 
 
Patients with NASH have significantly higher BMI and insulin resistance 
 
One of the major questions in NAFLD is to find a non-invasive diagnostic tool to distinguish 
patients at risk for NASH from patients with uncomplicated NAFLD. 
To screen for discrepancies in clinical parameters and laboratory values between NAFLD and 
NASH patients, we analysed the mean values of different parameters for each of the 57 
patients included into our NAFLD cohort study and followed from March 2003 until January 
2008. Differences were calculated using the Mann Whitney test. 
A clinical risk factor for the development of NAFLD is adiposity. It can be assessed by the 
body weight or the body mass index (BMI). Central adiposity, a consequence of visceral fat 
accumulation, has been considered worse than peripheral adiposity, a consequence of 
subcutaneous fat accumulation. Waist circumference is a parameter that roughly estimates the 
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amount of visceral fat. In our population we found that BMI (p=0.0465) and waist 
circumference (p=0.003), but not body weight alone (p=0.2380), are significantly higher in 
the NASH group (Figure 9A).  
We further found that insulin resistance, calculated by HOMA-IR, an important factor in the 
pathogenesis of NAFLD, is significantly higher in NASH than in NAFLD patients (p= 
0.0019). Also fasting glucose (p=0.02) and insulin (p=0.0011) are significantly higher in the 
NASH group (Figure 9B). 
In clinical practice, liver aspartate aminotransferase (AST), alanine aminotransferase (ALT) 
and ?-glutamyl transpeptidase (GGT) are measured in the blood in order to estimate the 
activity of hepatic inflammation. The ratio AST/ALT has been proposed to predict NASH in 
NAFLD (141). When comparing these hepatic enzymes in fasting blood samples we observe 
significantly higher values for AST (p=0.0122) but not ALT (p=0.3986) and GGT 
(p=0.1402) values (Figure 9C). 
In a multivariate regression analysis, HOMA-IR (p=0.01), fasting glucose (p=0.01) and 
fasting insulin (p=0.001) were significantly correlated with the diagnosis of NASH. Also 
AST (p=0.002) but not GGT (p=0.44) has been associated with NASH. BMI (p=0.02) also 
showed correlation with the diagnosis of NASH whereas weight (p=0.43) and waist 
circumference (p=0.12) were not associated. This correlation disappears (p=0.121) when we 
remove weight and waist circumference from the regression.  
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Figure 9: Differences in clinical and laboratory values between NAFLD and NASH patients. 
Data of 35 NASH and 22 NAFLD patients has been collected at preferentially all visits. 
Mean values of the different parameters were calculated for each patient and compared 
between the 2 groups of diagnosis by a non-parametric test (two-tailed Mann Whitney Test) 
(*, p<0.05; **, p<0.01). 
A. Weight (kg), BMI (kg/m2) and waist circumference (cm) were measured in all patients.  
B. Fasting glucose (mmol/l) and insulin (mIU/l) were measured in blood samples, HOMA-IR 
was calculated. 
C. AST (U/l), ALT (U/l) and GGT (U/l) were measured in fasting blood samples. 
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Cytokeratin-18 fragmentation is a parameter to distinguish NAFLD from NASH 
 
It recently has been proposed that assessment of cytokeratin-18 (CK-18) fragments in the 
blood might be used as a non-invasive marker to predict NASH in NAFLD (42, 43). CK-18 
fragmentation is believed to reflect liver cell apoptosis and therefore correlate with severity 
of NAFLD. CK-18 fragments have been measured in the blood of 44 patients with NAFLD 
and assigned to liver histology. A cutoff- value of 395 U/l of CK-18 fragments has been 
calculated and showed a specificity of 99.9% and a sensitivity of 87.5% to predict NASH 
(42). 
We measured CK-18 fragments in serum samples from 31 NASH and 16 NAFLD patients at 
their baseline visits. The value was assigned to histological diagnosis of NAFLD or NASH. 
In contrast to the original paper from Wieckowska et al., we did not assign a group of patients 
with borderline NASH. NASH patients had significantly higher CK-18 values (Median 245.6 
IU/l in NASH versus 163.4 IU/l in NAFLD, p= 0.0056, two-tailed Mann Whitney Test) 
(Figure 10). 
 
 
 
Figure 10: NASH patients have significantly higher CK-18 fragments than NAFLD patients. 
CK-18 fragments were measured in the serum of 31 NASH and 16 NAFLD patients at 
baseline. 
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5. Discussion 
 
1. Dysregulation of hepatic glucose metabolism by protein 
phosphatase 2A - a new mechanism for viral induced insulin resistance 
development 
 
Development of insulin resistance and type 2 diabetes mellitus involve highly complex 
systemic mechanisms that have not been clearly described yet. 
Viral induced insulin resistance in contrast is a more restricted scenario since it is primarily 
limited to the organs and tissues infected by the virus. In the case of hepatitis C studied in this 
work, presence of viral particles in the liver is regarded as the origin of insulin resistance 
development. 
There are at least two possibilities for the HCV virus to contribute to systemic insulin 
resistance: 
First the viral proteins could directly or indirectly interfere with glucose metabolism in the 
liver and thereby contribute to hepatic insulin resistance – inappropriate glucose regulation in 
the liver in response to insulin. This implies inappropriate glucose uptake, glycogen storage 
and increased hepatic glucose production and can lead to hyperglycemia and secondary to 
peripheral insulin resistance. 
Second the viral infection could induce cytokine production and release from activated 
mononuclear cells and immune competent cells in the liver. Cytokines would interfere with 
glucose metabolism in response to insulin in the liver and in peripheral organs leading to 
systemic insulin resistance. 
Evidence and model systems for both possibilities have been described. For instance, indirect 
interference of viral proteins with the insulin signaling pathway have been reported through 
the upregulation of SOCS-3 (142), SOCS-7 or activation of mTOR (127) mediated 
degradation of IRS-1. Upregulation of the cytokines IL-6 (136, 143) and TNF? (121, 137) in 
response to viral infection have also been proposed to interfere with the insulin signaling 
cascade and initiate insulin resistance development. 
Our work was initiated by the observation that protein phosphatase 2A is transcriptionally 
upregulated in the virus infected liver by induction of an ER stress response. Transcriptional 
upregulation of one of the major serine-/threonine phosphatases is a critical event as it can 
disturb multiple cellular signaling cascades in the liver that are controlled by serine-/ 
threonine phosphorylation. We have already reported inhibition of interferon signaling by 
PP2A (57). Researchers from a different laboratory had observed inhibition of insulin 
signaling by PP2A in adipocytes (131). Also ER stress has been implicated in pathogenesis of 
insulin resistance (65, 144). There is sufficient evidence to assume that virus induced PP2A 
upregulation in the liver might dysregulate signaling cascades that control glucose 
metabolism. 
In the work presented in this thesis we were able to establish a new model for virus induced 
insulin resistance development. We provide evidence in vitro and in vivo that overexpression 
of PP2A in the liver inhibits the insulin signaling pathway, AMPK phosphorylation and 
probably also LXR regulated inhibition of gluconeogenesis. PP2A therefore interferes with 
three different mechanisms involved in the control of hepatic glucose metabolism. 
Detailed analysis of the insulin signaling cascade revealed that PP2A directly or indirectly 
dephosphorylates and inactivates PKB/Akt, a kinase centrally involved in the pathway. 
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Contrary to others cited above (121, 126, 127, 142) but in accordance with Aytug et al., (130) 
we did not find inhibition of insulin signaling upstream of PKB/Akt. Further downstream 
signaling is decreased, here shown for GSK3? phosphorylation, but most likely also Foxo 
transcription factors, PGC1?, AS160 and other known substrates for PKB/Akt (85). 
Inhibition of insulin signaling at the level of PKB/Akt leads to decreased glucose uptake, 
decreased glycogen synthesis and impaired inhibition of gluconeogenesis contributing to 
hyperglycemia. We provide evidence that glycogen synthesis is impaired through 
hypophosphorylation of GSK3? unless there is debate about the substantial role for GSK3? 
in regulating glycogen synthase (145, 146). Further glucose uptake seems to be affected as 
we observed significantly lower expression of GLUT2 in HCV liver biopsies. We 
additionally observed that PGC1?, the main coactivator for gluconeogenic enzymes, is 
transcriptionally upregulated by PP2A in vivo and in vitro. PEPCK and G6Pase were also 
upregulated in vitro under high glucose conditions implying inappropriate increase of 
gluconeogenesis. Unexpectedly, this was not observed in vivo, neither in mouse- nor in 
human liver tissue. It is possible that differences in PEPCK and G6Pase cannot be observed 
under low glucose levels, when these enzymes are maximal expressed. Experiments in both 
mice and human were done in a fasted state. Further gluconeogenesis is regulated not only by 
transcriptional regulation of the required enzymes but also by enzyme activity in a function 
of the amount of substrates. To finally prove the concept that PP2A is upregulating hepatic 
glucose production we further need to study glucose production in the supernatant of 
hepatocytes that were transfected with a PP2Ac expressing construct. Additionally gene 
expression and enzymatic activity of PEPCK and G6Pase need to be analysed in B6HCV 
mice in the fed state. 
Gluconeogenesis is tightly controlled by AMP kinase that can be activated by metformin , a 
widely used and effective anti-diabetic drug. We show in cell culture and in HCV mice that 
PP2A dephosphorylates AMPK, thereby inhibiting its activity and its ability to suppress 
gluconeogenesis. Unfortunately, it is not feasible to study AMPK phosphorylation in human 
liver biopsies under routine conditions, because AMPK is phosphorylated due to ATP 
depletion within few minutes after obtaining the biopsy. These data provide evidence for 
PP2A dependent increase of PGC1? expression and gluconeogenesis. Regulation of AMPK 
by PP2A has been described in rat hepatocytes (104) and ?-cells (105). Supporting our model 
of PP2A as an important inhibitor of AMPK and other pathways of glucose metabolism, it 
has recently been published that palmitate, a saturated free fatty acid (FFA), would activate 
PP2A and hereby inhibit AMPK phosphorylation (106). FFAs in the circulating blood are 
increased in the insulin resistant state and play an important role in the maintenance of insulin 
resistance and fatty liver disease. As described, two different models have been published to 
clarify the mechanism by which metformin phosphorylates and activates AMPK (102, 103). 
It would be interesting to know whether metformin interferes with PP2A activity. 
Besides insulin and AMP/ATP levels, hepatic gluconeogenesis can be suppressed by glucose 
itself. We show that PP2A overexpression impairs glucose induced gene regulation in vitro 
by a yet unknown mechanism. Recently LXR have been implicated in glucose induced 
regulation of glucose- and lipid-metabolism (110). Glucose has an effect on LXR subcellular 
localization in ?-cells. High glucose conditions lead to nuclear translocation of LXR, 
probably regulated by LXR phosphorylation (116). Little is known about the role of LXR 
phosphorylation on serine 198 (115) but it might regulate its coactivator- or corepressor 
recruitment thereby changing its transcriptional activity (117). Changes in transcriptional 
activity due to phosphorylation have been described for other nuclear receptors, among them 
CAR, that is regulated by PP2A (119, 120). We speculate that PP2A dephosphorylates LXR. 
If LXR serine phosphorylation indeed changes transcriptional activity and glucose is a ligand 
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at LXR, this could explain why PP2A impairs glucose induced regulation of gluconeogenic 
genes.  
We propose a model here where virus induced upregulation of PP2A acts in a key position 
and interferes with three independently regulated pathways that control gluconeogenesis. 
Furthermore it negatively regulates glucose uptake and glycogensynthesis. 
 
 
2. Systemic insulin resistance and ER stress as a drug target 
 
It is of great interest to elucidate mechanisms of virus induced insulin resistance because 
insulin resistance itself might contribute to complications such as progression of hepatic 
fibrosis and resistance to antiviral drugs. Additional drugs counteracting insulin resistance 
development could help to avoid progressive forms of chronic hepatitis C and to improve 
response to antiviral therapy. 
Having pointed out a new mechanism of HCV interference with hepatic signaling pathways 
in glucose metabolism, we investigated its significance in systemic insulin resistance 
development in vivo. 
Little is known about the phenotype of the B6HCV transgenic mice studied here. It has been 
observed that up to 80% of animals develop steatosis and 60% show different patterns of 
inflammatory infiltration when they are older (124). Whether mice develop insulin resistance 
prior to steatosis and whether fibrosis or hepatocellular cancer formation occurs as a 
consequence of chronic inflammation has not been described. Another HCV genotype 1b 
transgenic mouse has been shown to develop insulin resistance and also diabetes, when fed 
with a high fat diet (121). 
We show for the first time that B6HCV mice have an insulin resistant phenotype with 
elevated levels of fasting glucose, fasting insulin and lower insulin tolerance at 3 months of 
age. From our gene expression analysis, we propose that PP2A dysregulates mainly 
gluconeogenesis through overexpression of PGC1? and leads to increased hepatic glucose 
production. To confirm this hypothesis, gluconeogenesis in B6HCV mice might be assessed 
by a radioactive assay measuring the amount of newly synthesized glucose from a C-14 
labeled alanine substrate.  
Having detected development of insulin resistance, we are further interested in the phenotype 
of B6HCV mice. As insulin resistance in HCV is associated with diverse consequences, we 
would like to study development of steatosis, steatohepatitis, fibrosis and eventually HCC in 
dependance of fasting glucose and –insulin. As described, free fatty acids, which are relaesed 
from the adipose tissue in the insulin resistant state, probably play a prominent role in the 
development of type 2 diabetes but also steatosis. We plan to feed B6HCV mice with high fat 
diets (HFD) consisting of different fat sources – saturated and unsaturated fatty acids. We 
expect accelerated development of steatosis and eventually steatohepatitis and fibrosis 
compared to mice on a regular diet. Further we would expect development of overt diabetes 
in mice on HFD, especially in the saturated free fatty acid group. It has been shown recently 
that palmitic acid, a saturated free fatty acid, acitvates PP2A and inhibits AMPK 
phosphorylation whereas oleic acid, a monounsaturated free fatty acid, did not (106). In our 
mouse model, where hepatic PP2A expression is increased, the different free fatty acid 
composition might influence the insulin resistant state and histologic findings. 
In human HCV liver biopsies we show that PP2A is upregulted and inhibits insulin signaling. 
Gene regulation analysis shows an upregulation of gluconeogenesis by PGC1? and decreased 
glucose uptake by GLUT2. Our data hint at a phenotype of hepatic insulin resistance. From 
the literature we know that HCV patients have elevated HOMA levels, a parameter for 
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systemic insulin resistance (14-18). We propose a model where PP2A induces hepatic insulin 
resistance leading to increased hepatic glucose production and decreased uptake. 
Hyperglycemia then might contribute to systemic insulin resistance with involvement of 
adipose tissue and muscle and development of compensatory hyperinsulinemia that is 
assessed by the HOMA-IR. In a large number of patients we did not observe a correlation 
between hepatic PP2A expression or the phosphorylation levels of PKB/Akt with HOMA-IR, 
supporting a two step model leading to systemic insulin resistance in chronic heapatitis C. 
The mechanism developed here is caused by virus induced ER stress (70). ER stress is 
increased in the liver under diabetic conditions (65, 147, 148). A drug preventing ER stress 
would eventually prevent the diverse consequences on hepatic and systemic insulin 
resistance. Chemical chaperones such as 4-phenyl butyric acid (4-PBA), trimethylamine N-
oxide dihydrate (TMAO) and dimethyl sulfoxide are low molecular weight compounds that 
stabilize protein conformation, improve protein folding und trafficking (64). Further bile acid 
derivates as tauroursodeoxycholic acid (TUDCA) can modulate ER function (149). It has 
been described in a mouse model of type 2 diabetes mellitus (leptin deficient ob/ob mice) that 
4-PBA and TUDCA can restore glucose homeostasis by the prevention of ER stress (66). 
UDCA is a drug widely used in cholestatic liver disease and has no severe side effects. Its use 
in the treatment of steatohepatitis is discussed controversely, while a large study in 2004 did 
not find benefit for UDCA compared to placebo (150), one recent study shows reduction in 
ALT values and in hepatic steatosis by UDCA (151). In Hepatitis C, UDCA also lead to 
decrease in ALT values but its ability to prevent disease progression has not been shown yet 
(152, 153). One the other hand it has been shown that bile acids can promote HCV 
replication in cells (154) disencouraging their use in chronic hepatitis C. Chemical 
chaperones have not been tested in clinical trials yet. 
To evaluate the effect of ER stress preventing agents as drugs for insulin resistance in 
hepatitis C, we consider feeding B6HCV mice with TUDCA or 4-PBA and study the effect 
on hepatic insulin signaling and systemic insulin sensitivity. If the experiments show a 
beneficial effect of these agents, they might be used as preventive drugs in chronic HCV 
infection. 
 
 
3. Insulin resistance and apoptosis in the progression of NAFLD 
 
Since introduction of the historical “two hit hypothesis” for pathogenesis of NAFLD it has 
been stressed repeatedly that insulin resistance plays a prominent role. Sequential resistance 
of peripheral tissues and the liver to insulin has been hypothesized (134). Hereby including 
the role of increasing free fatty acids from the insufficient suppression of lipolysis and 
increased FFA production in the insulin resistant state. However the precise mechanisms are 
still unknown. Cell injury may occur when the capacity of cells to safely store fat is 
overextended and fatty acids become toxic to the cell and induce so called “lipotoxicity”, 
apoptosis induced by fatty acids (155). 
Preliminary multivariate regression analysis of our cohort of NAFLD and NASH patients 
shows that NASH is independently associated with insulin resistance. This result confirms a 
key role for insulin resistance in the pathogenesis of NASH. 
Cytokeratin-18 fragments in the blood have been proposed to predict NASH, as a non-
invasive marker for liver cell apoptosis (42, 43). In accordance with this, analysis of CK-18 
fragmentation in our cohort reveals that NASH patients have significantly higher CK-18 
fragments. 
 49 
Searching for a parameter to predict NASH, also insulin resistance by HOMA might be a 
potential candidate. Further AST is independently associated with NASH whereas GGT and 
ALT are not. An AST/ALT or AST/GGT ratio might therefore be good parameters. 
AST/ALT ratio >1 has already been proposed to predict advanced fibrosis in NAFLD (141). 
We furthermore propose that measurement of CK-18 fragments by ELISA should be 
established as a routine test and would be useful in combination with the other clinical 
parameters discussed above. However, these methods can so far not replace the histological 
assessment of the diagnosis. 
It is not clear whether BMI has a significant influence on NASH but both body weight alone 
and waist circumference were not related to the diagnosis. The fact that waist circumference 
is not related to NASH queries the current model of waist-to-hip ratio. It is believed that 
visceral fat, roughly estimated by measuring the waist circumference, is more harmful than 
subcutaneous fat. In the insulin resistant state, FFA from visceral fat but not the subcutaneous 
fat would directly enter the liver by the portal vein. We did not observe any correlation 
between the waist circumference and NASH and should therefore reconsider the method to 
estimate visceral fat and the current hypothesis described above. 
Until present we do not have the collective for longitudinal analysis of these parameters. The 
development of HOMA, insulin and glucose, respectively, but also CK-18 fragments over 
time and dependent on the histological diagnosis will be interesting to observe. We further 
would like to study the predictive value of these parameters by comparison to a second liver 
biopsy 5 to 10 years after the initial biopsy. Correlation of development in both histology and 
serum markers could define non-invasive methods to distinguish NAFLD from NASH. 
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6. Summary 
 
The work presented here analyses the role of PP2A in the dysregulation of glucose 
metabolism in the setting of chronic hepatitis C. We propose a new model for virus induced 
insulin resistance development through the overexpression of PP2A in the liver that leads to 
hyperglycemia mainly through the inappropriate inhibition of hepatic gluconeogenesis. 
By dephosphorylation of key targets, PP2A upregulation interferes with three differently 
regulated pathways that control hepatic glucose metabolism schematically shown in figure 
11. First, it interferes with the insulin signaling cascade (right) by dephosphorylation of 
PKB/Akt, thereby upregulating gluconeogenesis and inhibiting glycogensynthesis. Second, it 
dephosphorylates AMPK and therefore again increases gluconeogenesis (center). And finally 
glucose induced regulation of gluconeogenesis is impaired through PP2A upregulation and 
eventually involves regulation of LXR (left). 
This concept has been developed in cell culture, but in a model of HCV transgenic mice we 
show that hepatic PP2A overexpression and dysregulation of these signaling pathways 
presents concomitantly with an insulin resistant phenotype. Similary, in patients infected with 
chronic hepatitis C we observed upregulation of PP2A and inhibition of hepatic insulin 
signaling, supporting its significance in vivo. 
A model explaining HCV induced insulin resistance development can help to understand 
disease progression to liver cirrhosis and resistance to antiviral therapy. It further discloses 
new drug targets in order to prevent these complications. 
 
 
 
Figure 11: Model for PP2A interference with glucose regulating pathways in the liver 
 
Concerning the clinical course of NAFLD and NASH, respectively, preliminary data from 
our observational study support the importance of insulin resistance and liver cell apoptosis 
in the pathophysiology of disease progression. We further confirm the use of CK-18 
fragmentation in the blood as a non-invasive marker predicting NASH. 
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